Study finds single-use bronchoscopes reduce hospital readmission rates by half

The Ambu aScope4 single-use bronchoscope [Photo courtesy of Ambu]A study of 14,228 bronchoscopy procedures found sterile, disposable scopes reduced readmission rates by more than half.

The study, authored by Ambu consultant Dr. Hudson Garrett, analyzed procedures at inpatient hospitals as well as outpatient ambulatory facilities.

He found that 3.6 percent of patients treated with a single-use, flexible bronchoscope were readmitted within 30 days, compared to 7.7 percent of patients whose procedures used reusable scopes.

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Medtronic hires social-media-minded chief medical officer for its gastrointestinal unit

Dr. Austin Chiang is chief medical officer of Medtronic’s Gastrointestinal business [Photo courtesy of Medtronic]Medtronic (NYSE:MDT) today said it has hired Dr. Austin Chiang as the first chief medical officer of the medical device maker’s gastrointestinal business.

Chiang is an assistant professor of medicine at Sidney Kimmel Medical College and director of the Endoscopic Bariatric Program at Thomas Jefferson University Hospital, both in Philadelphia. He has a master’s degree in public health from the Harvard T.H. Chan School of Public Health.

Chiang holds the unusual position of chief medical social media officer of Jefferson Health, reflecting his advocacy for using online channels for education and outreach about GI-related conditions and current events in healthcare.

Get the full story on our sister site, Medical Design & Outsourcing.

Read more
  • 0

Danaher slides despite Street-beating Q3

Danaher (NYSE:DHR) shares dipped today even as the company registered third-quarter results that topped the consensus forecast.

The Washington, D.C.-based company posted profits of $1.2 billion, or $1.54 per share, on sales of $7.2 billion for the three months ended Sept. 30, 2021, for a 31.1% bottom-line gain on sales growth of 22.9%.

Adjusted to exclude one-time items, earnings per share were $2.39, 24¢ ahead of Wall Street, where analysts were looking for sales of $7 billion.

“Our team delivered another outstanding result in the third quarter, with over 20% core revenue growth and terrific earnings and cash flow performance.  We continued to invest for growth across our businesses, expanding production capacity and accelerating innovation initiatives,” Danaher President & CEO Rainer M. Blair said in a news release. “Additionally, the recently closed acquisition of Aldevron enhances our portfolio and expands our capabilities into …

Read more
  • 0

Eli Lilly touts data for tirzepatide compared to insulin glargine for type 2 diabetes

Eli Lilly (NYSE:LLY) announced positive results from a trial comparing tirzepatide to titrated insulin glargine in adults with type 2 diabetes.

Indianapolis-based Eli Lilly’s Surpass-4 clinical trial demonstrated that adults with type 2 diabetes and increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

DarioHealth unveils digital therapy for treating musculoskeletal conditions

DarioHealth (NSDQ:DRIO) announced that it launched Dario Move, a digital physical therapy platform for musculoskeletal (MSK) conditions.

With the introduction of the Dario Move, Boston-based Dario adds to its suite of chronic condition management platforms that include treatments for diabetes, behavioral health and metabolic health, according to a news release.

Dario Move combines software, technology and professional human support with features including a single biofeedback sensor for ease of use, personalized evidence-based exercise programs designed by physical therapists, real-time feedback and support and a highly personalized experience across Dario’s full suite of chronic condition solutions.

“The launch of Dario Move marks a significant achievement for our company, as we successfully and efficiently integrated the Upright MSK solution into our comprehensive multi-chronic condition digital therapeutics platform, further expanding its …

Read more
  • 0

J&J Institute, DePuy Synthes launch mobile training lab for Velys robotic surgery platform

Image from Depuy Synthes/Johnson & Johnson

DePuy Synthes and the Johnson & Johnson Institute launched a mobile training lab for surgeons using the Velys robot-assisted platform.

The first-of-its-kind mobile training lab offering next-generation training directly to surgeons and their teams was launched in Sydney, Australia, according to a news release.

DePuy Synthes, the orthopaedics business unit of Johnson & Johnson, will offer on-site access to the training along with virtual reality-based operating environments and real-time collaboration at the Velys Digital Surgery Mobile Lab. All of the offerings intend to equip Australian orthopaedic surgeons with the capabilities to proficiently use the Velys robotic-assisted solution.

Velys, a first-of-its kind, table-mounted solution offers an efficient design capable of integrating into any operating room, the company said. DePuy said it adapts to a surgeon’s workflow, offers control they are used…

Read more
  • 0

Luminopia’s new FDA-approved therapy uses TV to treat lazy eye in kids

Luminopia announced today that it received FDA de novo approval for its prescription therapy for improving vision in children with lazy eye.

Cambridge, Massachusetts-based Luminopia’s prescription Luminopia One holds indication for improvement in visual acuity in children between ages four and seven with lazy eye (amblyopia) associated with anisometropia and/or mild strabismus, having received treatment instructions as prescribed by a trained eye-care professional, according to a news release.

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Diversity in medtech: Just 21% of executive roles are held by women

The prevalence of women in corporate leadership positions within the medical device industry remains low, and the rate of increase is stagnant despite new initiatives to increase diversity in the industry.

Just 21% of top executives at the world’s 100 world’s biggest medical device companies are women, according to an analysis of Medical Design & Outsourcing‘s annual Big 100 breakdown of the top revenue-generating medical device companies in the world.

The analysis involved seeing who shows up on the leadership pages on the corporations’ websites. While the overall number of women executives on such pages is up 1 percentage point from 2020, the average percentage of women in medtech companies’ top executive ranks remained unchanged from last year at 19%.

“The medtech workforce must mirror the patients we serve if we are going to succeed in delivering innovative technology to populations who need it,” AdvaMed chief financial officer and chief operatin…

Read more
  • 0

Medtronic touts data for MiniMed 780G insulin pump in children

Medtronic (NYSE:MDT) reported positive one-year, real-world clinical data for its MiniMed 780G insulin pump platform in children.

Data came from a subset of 3,211 pediatric and adolescent patients (15 years old and below) with type 1 diabetes using the MiniMed 780G system with the Guardian Sensor 3 in Europe.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Medtronic warns on Percept PC implantable neurostimulators

Medtronic (NYSE:MDT) has issued an urgent field safety notice in Europe to warn of issues with its Percept PC implantable neurostimulator.

The notice’s purpose stands to inform customers of the potential failure with the Model B35200 Percept PC INS following a cardioversion procedure.

Fridley, Minnesota-based Medtronic determined that cardioversion may damage the electronics in the Percept PC INS device, making the INS unresponsive and non-functional, leaving the INS incapable of being turned back on, according to the notice. If therapy ceases, it will likely cause the return of disease symptoms.

In some cases, symptoms may return with a greater intensity than previously experienced by the user prior to implantation, which, in rare cases, can constitute a medical emergency.

Medtronic received four complaints on the issue from patients implanted with Percept PC between Jan. 14, 2020, and Oct. 4, 2021. All reported issues have resulted in or a…

Read more
  • 0

Abbott rises on Street-beating Q3, increased EPS guidance

Abbott (NYSE:ABT) shares ticked up this morning on third-quarter results that easily topped the consensus forecast.

The Abbott Park, Illinois-based company posted profits of $2.1 billion, or $1.17 per share, on sales of $10.9 billion for the three months ended Sept. 30, 2021, for a 70.5% bottom-line gain on sales growth of 23.4%.

Adjusted to exclude one-time items, earnings per share were $1.40, 46¢ ahead of Wall Street, where analysts were looking for sales of $9.6 billion.

The company’s medical device business registered revenues of $3.6 billion, representing a year-over-year increase of 14.6%. Abbott’s diagnostics business, bolstered by its COVID-19 testing products like the over-the-counter BinaxNow rapid diagnostic, saw 48.2% growth to revenues of $3.9 billion for the quarter.

“We achieved another quarter of strong growth overall and across all four of our major business areas,” Abbott president & CEO Robert B. For…

Read more
  • 0